Abiraterone acetate ( DrugBank: Abiraterone, Acetate )


2 diseases
IDDisease name (Link within this page)Number of trials
75Cushing disease2
81Congenital adrenal hyperplasia3

75. Cushing disease


Clinical trials : 205 Drugs : 176 - (DrugBank : 45) / Drug target genes : 61 - Drug target pathways : 127
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03145285
(ClinicalTrials.gov)
April 18, 201726/4/2017Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical CarcinomaActivity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical CarcinomaCushing Syndrome;Adrenocortical CarcinomaDrug: Abiraterone AcetateAzienda Ospedaliera Spedali Civili di BresciaFondazione IRCCS Istituto Nazionale dei Tumori, Milano;Niguarda Hospital;San Camillo Hospital, Rome;San Luigi Gonzaga HospitalActive, not recruiting18 YearsN/AAll10Phase 2Italy
2EUCTR2016-000945-29-IT
(EUCTR)
16/06/201604/11/2020Activity of Abiraterone Acetate in the management of Cushing’s syndrome in patients with adrenocortical carcinoma (ABACUS)Activity of Abiraterone Acetate in the management of Cushing’s syndrome in patients with adrenocortical carcinoma (ABACUS) - ABACUS Cushing’s syndrome in patients with adrenocortical carcinoma
MedDRA version: 20.0;Level: PT;Classification code 10001388;Term: Adrenocortical carcinoma;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04]
Trade Name: ZYTIGA - 250 MG - COMPRESSA - USO ORALE - FLACONE 120 COMPRESSE
Product Name: ZYTIGA
Product Code: [ZYTIGA]
INN or Proposed INN: abiraterone acetato
AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIANULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
30Phase 2Italy

81. Congenital adrenal hyperplasia


Clinical trials : 87 Drugs : 87 - (DrugBank : 23) / Drug target genes : 12 - Drug target pathways : 68
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03548246
(ClinicalTrials.gov)
January 202324/4/2015Androgen Reduction in Congenital Adrenal HyperplasiaA Phase 1-2 Multi-Center Study to Assess the Efficacy and Safety of Abiraterone Acetate as Adjunctive Therapy in Pre-Pubescent Children With Classic 21-Hydroxylase DeficiencyCongenital Adrenal HyperplasiaDrug: Abiraterone acetate;Drug: Placebo;Drug: Hydrocortisone;Drug: FludrocortisoneUniversity of Texas Southwestern Medical CenterNational Institutes of Health Clinical Center (CC);University of Michigan;Children's Hospital Los Angeles;Feinstein Institute for Medical ResearchWithdrawn2 Years9 YearsAll0Phase 2United States
2NCT02574910
(ClinicalTrials.gov)
August 1, 201724/4/2015Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1A Phase 1 Multi-Center Study to Assess the Efficacy and Safety of Abiraterone Acetate as Adjunctive Therapy in Pre-Pubescent Children With Classic 21-Hydroxylase DeficiencyCongenital Adrenal HyperplasiaDrug: Abiraterone acetateUniversity of Texas Southwestern Medical CenterEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);University of Michigan;Children's Hospital Los AngelesActive, not recruiting2 Years9 YearsAll36Phase 1United States
3NCT01495910
(ClinicalTrials.gov)
December 201123/11/2011A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase DeficiencyAn Open-Label, Multiple-Dose, Dose-Finding Study of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency21-hydroxylase DeficiencyDrug: Abiraterone acetateJohnson & Johnson Pharmaceutical Research & Development, L.L.C.NULLCompleted18 YearsN/AFemale6Phase 1United States